Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
Y Pang, N Ghosh - Frontiers in Oncology, 2024 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin
lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies …
lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies …
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
G Agliardi, J Dias, A Rampotas, J Garcia… - The Lancet …, 2024 - thelancet.com
Autologous chimeric antigen receptor (CAR) T-cell therapy has transformed the
management of B-cell leukaemia and lymphoma. However, current manufacturing …
management of B-cell leukaemia and lymphoma. However, current manufacturing …
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting
J Yang, H Guo, L Han, Y Song, K Zhou - Experimental Hematology & …, 2024 - Springer
Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has
been employed in the management of hematological malignancies to mitigate treatment …
been employed in the management of hematological malignancies to mitigate treatment …